0000899243-21-007278.txt : 20210218 0000899243-21-007278.hdr.sgml : 20210218 20210218212422 ACCESSION NUMBER: 0000899243-21-007278 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210216 FILED AS OF DATE: 20210218 DATE AS OF CHANGE: 20210218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brenner Malcolm CENTRAL INDEX KEY: 0001818068 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 21651825 MAIL ADDRESS: STREET 1: C/O ALLOVIR, INC. STREET 2: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-16 0 0001754068 Allovir, Inc. ALVR 0001818068 Brenner Malcolm C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2021-02-16 4 S 0 5120 41.7518 D 1013543 I See Footnote Common Stock 2021-02-16 4 S 0 1000 42.2495 D 1012543 I See Footnote Common Stock 2021-02-16 4 S 0 100 43.13 D 1012443 I See Footnote Common Stock 2021-02-17 4 S 0 1200 38.6606 D 1011243 I See Footnote Common Stock 2021-02-17 4 S 0 1000 39.966 D 1010243 I See Footnote Common Stock 2021-02-17 4 S 0 2765 41.2906 D 1007478 I See Footnote Common Stock 2021-02-17 4 S 0 200 41.99 D 1007278 I See Footnote Common Stock 30197 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.10 to $42.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.10 to $42.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.16 to $39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.60 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.89 to $41.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. /s/ Brett Hagen, as Attorney-in-Fact 2021-02-18